96 results
Page 3 of 5
8-K
EX-99.2
j5fxmzwk6t xm093c
11 Mar 22
Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
7:04am
8-K
EX-99.2
93b1w
15 Feb 22
Clene Nanomedicine Provides Clinical Program Update
7:01am
8-K
EX-10.3
vm2og4
2 Feb 22
Clene Announces New Chief Financial Officer Morgan Brown
12:00am
8-K
EX-10.1
klgrjeejk6
2 Feb 22
Clene Announces New Chief Financial Officer Morgan Brown
12:00am
8-K
EX-10.4
hnv84pw8x9f 9q1
2 Feb 22
Clene Announces New Chief Financial Officer Morgan Brown
12:00am
8-K
EX-99.1
rq0 1tre0v
17 Dec 21
Regulation FD Disclosure
12:00am
8-K
EX-99.2
st63lwrp3wp6h
1 Dec 21
Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
7:05am
424B3
ucgemmtw
10 Nov 21
Prospectus supplement
4:02pm
424B3
zudbvbplxwx7kys7igo
10 Nov 21
Prospectus supplement
4:01pm
8-K
EX-99.2
wli4geux 4cr4914unx
9 Nov 21
Clene Reports Third Quarter 2021 Operating and Financial Highlights
7:01am
8-K
EX-99.2
nh8u4mdrn46 8kqtv
17 Sep 21
Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021
7:06am
424B3
5lqjip
11 Aug 21
Prospectus supplement
4:01pm
424B3
r8bvj qn9t9ycrjoow
11 Aug 21
Prospectus supplement
4:00pm
8-K
EX-10.2
iov6pkzvipq90 ggo6
11 Aug 21
Entry into a Material Definitive Agreement
7:05am
8-K
EX-10.1
4r85l32lpe1 4u4znk
11 Aug 21
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.2
0j0mq0xjsdt6rvi
10 Aug 21
Clene Reports Second Quarter 2021 Operating and Financial Highlights
7:06am
8-K
EX-99.2
f39gd b7js98
5 Aug 21
Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis
7:05am